Gathering the record
Relay is organizing the evidence and source boundaries.
Amino-acid derivative
A substance the body uses to turn fat into energy. Approved levocarnitine products treat specific deficiencies.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Approved labels support defined deficiency indications; pooled weight-related trials report small average changes with substantial heterogeneity.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Labels describe gastrointestinal effects, body odor, seizure-related cautions, and serious hypersensitivity with intravenous use; individual risk depends on route and clinical context.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceLabels describe gastrointestinal effects, body odor, seizure-related cautions, and serious hypersensitivity with intravenous use; individual risk depends on route and clinical context.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Instructions from the named approved product’s prescribing information. They apply to its stated formulation, route, use, and population.
Carnitor labeling addresses diagnosed carnitine deficiency. The tablet reference is distinct from injection and oral-solution instructions.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| Monitored deficiency treatment | 990 mg using 330 mg tablets | 2 or 3 times daily, depending on clinical response |
Deficiency replacement is not a fat-loss indication or an injection schedule for non-deficient users. The label calls for clinical and biochemical monitoring.
Carnitor · U.S. prescribing information, tablets Prescribing information · Dosage and administrationThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This reference is for oral tablets. There is no powder reconstitution or syringe conversion.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
The Carnitor product label describes levocarnitine replacement for diagnosed carnitine deficiency. This is a regulatory reference, not a published treatment series.
Population: People with primary carnitine deficiency
Design: Regulatory product-label reference; not a treatment-series publication
Mechanisms
Levocarnitine replacement corrects defined deficiency states. Trials and meta-analyses in people without a diagnosed deficiency address different formulations, populations, and endpoints and should not be conflated with approved replacement therapy.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Mature deficiency-treatment evidence; heterogeneous and generally modest evidence for body-weight outcomes.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Which non-deficient populations, if any, have clinically meaningful benefit and how route, baseline status, and duration change outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A rare deficiency population is biologically different from people with normal carnitine status. The record supports replacement in a defined condition, not general weight, exercise, energy, or wellness claims. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Systematic review and meta-analysis of randomized trials
Adults across multiple clinical contexts
Across heterogeneous randomized trials, supplementation was associated with a small average reduction in body weight.
Study administration: Not stated in the current record.
Limitations: Heterogeneous populations, formulations, durations, and trial quality; average effect does not establish individual benefit.
Regulatory product-label reference; not a treatment-series publication
People with primary carnitine deficiency
Endpoints were not fully described in the current record.
The product label describes levocarnitine replacement for primary systemic carnitine deficiency and specified secondary deficiency contexts.
Study administration: Oral levocarnitine in the named Carnitor presentations
Limitations: Rare deficiency treatment does not establish benefit in non-deficient populations.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 32359762